nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—MYT1—nervous system—Gilles de la Tourette syndrome	0.0177	0.0193	CbGeAlD
Dasatinib—MYT1—central nervous system—Gilles de la Tourette syndrome	0.0171	0.0186	CbGeAlD
Dasatinib—MYT1—brain—Gilles de la Tourette syndrome	0.0135	0.0147	CbGeAlD
Dasatinib—EPHB1—nervous system—Gilles de la Tourette syndrome	0.0118	0.0129	CbGeAlD
Dasatinib—EPHB1—central nervous system—Gilles de la Tourette syndrome	0.0114	0.0124	CbGeAlD
Dasatinib—SIK2—nervous system—Gilles de la Tourette syndrome	0.0104	0.0114	CbGeAlD
Dasatinib—PKMYT1—nervous system—Gilles de la Tourette syndrome	0.0102	0.0111	CbGeAlD
Dasatinib—SIK2—central nervous system—Gilles de la Tourette syndrome	0.0101	0.0109	CbGeAlD
Dasatinib—PKMYT1—central nervous system—Gilles de la Tourette syndrome	0.0098	0.0107	CbGeAlD
Dasatinib—EPHB2—nervous system—Gilles de la Tourette syndrome	0.00971	0.0106	CbGeAlD
Dasatinib—SIK3—midbrain—Gilles de la Tourette syndrome	0.00963	0.0105	CbGeAlD
Dasatinib—SRMS—nervous system—Gilles de la Tourette syndrome	0.0095	0.0103	CbGeAlD
Dasatinib—EPHB2—central nervous system—Gilles de la Tourette syndrome	0.00935	0.0102	CbGeAlD
Dasatinib—EPHA8—nervous system—Gilles de la Tourette syndrome	0.00931	0.0101	CbGeAlD
Dasatinib—SRMS—central nervous system—Gilles de la Tourette syndrome	0.00915	0.00996	CbGeAlD
Dasatinib—EPHB1—brain—Gilles de la Tourette syndrome	0.00904	0.00984	CbGeAlD
Dasatinib—EPHA8—central nervous system—Gilles de la Tourette syndrome	0.00896	0.00976	CbGeAlD
Dasatinib—STAT5B—nervous system—Gilles de la Tourette syndrome	0.0088	0.00959	CbGeAlD
Dasatinib—EPHA5—midbrain—Gilles de la Tourette syndrome	0.00876	0.00954	CbGeAlD
Dasatinib—STAT5B—central nervous system—Gilles de la Tourette syndrome	0.00847	0.00923	CbGeAlD
Dasatinib—EPHA3—nervous system—Gilles de la Tourette syndrome	0.00814	0.00886	CbGeAlD
Dasatinib—SIK2—brain—Gilles de la Tourette syndrome	0.00798	0.00869	CbGeAlD
Dasatinib—SIK3—nervous system—Gilles de la Tourette syndrome	0.00791	0.00862	CbGeAlD
Dasatinib—TESK1—midbrain—Gilles de la Tourette syndrome	0.00791	0.00862	CbGeAlD
Dasatinib—EPHA3—central nervous system—Gilles de la Tourette syndrome	0.00783	0.00853	CbGeAlD
Dasatinib—PKMYT1—brain—Gilles de la Tourette syndrome	0.00778	0.00847	CbGeAlD
Dasatinib—SIK3—central nervous system—Gilles de la Tourette syndrome	0.00762	0.0083	CbGeAlD
Dasatinib—EPHB2—brain—Gilles de la Tourette syndrome	0.00742	0.00808	CbGeAlD
Dasatinib—ZAK—nervous system—Gilles de la Tourette syndrome	0.00736	0.00801	CbGeAlD
Dasatinib—STK35—midbrain—Gilles de la Tourette syndrome	0.0073	0.00795	CbGeAlD
Dasatinib—SRMS—brain—Gilles de la Tourette syndrome	0.00726	0.00791	CbGeAlD
Dasatinib—CSK—midbrain—Gilles de la Tourette syndrome	0.00725	0.00789	CbGeAlD
Dasatinib—EPHA5—nervous system—Gilles de la Tourette syndrome	0.0072	0.00784	CbGeAlD
Dasatinib—LYN—nervous system—Gilles de la Tourette syndrome	0.00716	0.0078	CbGeAlD
Dasatinib—HCK—midbrain—Gilles de la Tourette syndrome	0.00715	0.00779	CbGeAlD
Dasatinib—EPHA8—brain—Gilles de la Tourette syndrome	0.00711	0.00775	CbGeAlD
Dasatinib—ZAK—central nervous system—Gilles de la Tourette syndrome	0.00708	0.00771	CbGeAlD
Dasatinib—BMPR1B—nervous system—Gilles de la Tourette syndrome	0.00705	0.00768	CbGeAlD
Dasatinib—MAP3K19—nervous system—Gilles de la Tourette syndrome	0.00705	0.00768	CbGeAlD
Dasatinib—EPHA5—central nervous system—Gilles de la Tourette syndrome	0.00693	0.00755	CbGeAlD
Dasatinib—TNK2—nervous system—Gilles de la Tourette syndrome	0.00692	0.00753	CbGeAlD
Dasatinib—LYN—central nervous system—Gilles de la Tourette syndrome	0.0069	0.00751	CbGeAlD
Dasatinib—BMPR1B—central nervous system—Gilles de la Tourette syndrome	0.00679	0.0074	CbGeAlD
Dasatinib—MAP3K19—central nervous system—Gilles de la Tourette syndrome	0.00679	0.0074	CbGeAlD
Dasatinib—STAT5B—brain—Gilles de la Tourette syndrome	0.00673	0.00733	CbGeAlD
Dasatinib—RIPK2—midbrain—Gilles de la Tourette syndrome	0.00673	0.00733	CbGeAlD
Dasatinib—TNK2—central nervous system—Gilles de la Tourette syndrome	0.00666	0.00725	CbGeAlD
Dasatinib—TESK1—nervous system—Gilles de la Tourette syndrome	0.0065	0.00708	CbGeAlD
Dasatinib—ERBB3—midbrain—Gilles de la Tourette syndrome	0.00644	0.00701	CbGeAlD
Dasatinib—EPHB3—nervous system—Gilles de la Tourette syndrome	0.0064	0.00697	CbGeAlD
Dasatinib—STK36—nervous system—Gilles de la Tourette syndrome	0.0064	0.00697	CbGeAlD
Dasatinib—TESK1—central nervous system—Gilles de la Tourette syndrome	0.00626	0.00682	CbGeAlD
Dasatinib—EPHA3—brain—Gilles de la Tourette syndrome	0.00622	0.00677	CbGeAlD
Dasatinib—LIMK2—nervous system—Gilles de la Tourette syndrome	0.00619	0.00674	CbGeAlD
Dasatinib—STK36—central nervous system—Gilles de la Tourette syndrome	0.00616	0.00671	CbGeAlD
Dasatinib—EPHB3—central nervous system—Gilles de la Tourette syndrome	0.00616	0.00671	CbGeAlD
Dasatinib—SIK3—brain—Gilles de la Tourette syndrome	0.00605	0.00659	CbGeAlD
Dasatinib—STK35—nervous system—Gilles de la Tourette syndrome	0.006	0.00653	CbGeAlD
Dasatinib—CSK—nervous system—Gilles de la Tourette syndrome	0.00596	0.00649	CbGeAlD
Dasatinib—LIMK2—central nervous system—Gilles de la Tourette syndrome	0.00596	0.00649	CbGeAlD
Dasatinib—HCK—nervous system—Gilles de la Tourette syndrome	0.00588	0.00641	CbGeAlD
Dasatinib—STK35—central nervous system—Gilles de la Tourette syndrome	0.00577	0.00629	CbGeAlD
Dasatinib—CSK—central nervous system—Gilles de la Tourette syndrome	0.00574	0.00625	CbGeAlD
Dasatinib—EPHB4—midbrain—Gilles de la Tourette syndrome	0.00568	0.00619	CbGeAlD
Dasatinib—HCK—central nervous system—Gilles de la Tourette syndrome	0.00566	0.00617	CbGeAlD
Dasatinib—ZAK—brain—Gilles de la Tourette syndrome	0.00562	0.00612	CbGeAlD
Dasatinib—FYN—midbrain—Gilles de la Tourette syndrome	0.00557	0.00606	CbGeAlD
Dasatinib—EPHA5—brain—Gilles de la Tourette syndrome	0.0055	0.00599	CbGeAlD
Dasatinib—LYN—brain—Gilles de la Tourette syndrome	0.00547	0.00596	CbGeAlD
Dasatinib—MAP3K3—midbrain—Gilles de la Tourette syndrome	0.00544	0.00592	CbGeAlD
Dasatinib—MAP4K5—midbrain—Gilles de la Tourette syndrome	0.00544	0.00592	CbGeAlD
Dasatinib—SIK1—nervous system—Gilles de la Tourette syndrome	0.0054	0.00588	CbGeAlD
Dasatinib—BMPR1B—brain—Gilles de la Tourette syndrome	0.00539	0.00587	CbGeAlD
Dasatinib—MAP3K19—brain—Gilles de la Tourette syndrome	0.00539	0.00587	CbGeAlD
Dasatinib—BTK—brain—Gilles de la Tourette syndrome	0.00537	0.00584	CbGeAlD
Dasatinib—EPHA4—nervous system—Gilles de la Tourette syndrome	0.00535	0.00582	CbGeAlD
Dasatinib—ERBB3—nervous system—Gilles de la Tourette syndrome	0.00529	0.00576	CbGeAlD
Dasatinib—TNK2—brain—Gilles de la Tourette syndrome	0.00529	0.00576	CbGeAlD
Dasatinib—MAP3K2—nervous system—Gilles de la Tourette syndrome	0.00524	0.00571	CbGeAlD
Dasatinib—SIK1—central nervous system—Gilles de la Tourette syndrome	0.0052	0.00566	CbGeAlD
Dasatinib—EPHB6—midbrain—Gilles de la Tourette syndrome	0.0052	0.00566	CbGeAlD
Dasatinib—EPHA4—central nervous system—Gilles de la Tourette syndrome	0.00515	0.00561	CbGeAlD
Dasatinib—JAK2—Serotonin Receptor 2 and STAT3 Signaling—HTR2A—Gilles de la Tourette syndrome	0.00511	0.0625	CbGpPWpGaD
Dasatinib—ERBB3—central nervous system—Gilles de la Tourette syndrome	0.0051	0.00555	CbGeAlD
Dasatinib—MAP3K2—central nervous system—Gilles de la Tourette syndrome	0.00505	0.0055	CbGeAlD
Dasatinib—YES1—midbrain—Gilles de la Tourette syndrome	0.00502	0.00547	CbGeAlD
Dasatinib—TESK1—brain—Gilles de la Tourette syndrome	0.00497	0.00541	CbGeAlD
Dasatinib—MAPK14—nervous system—Gilles de la Tourette syndrome	0.00493	0.00537	CbGeAlD
Dasatinib—FGR—nervous system—Gilles de la Tourette syndrome	0.00491	0.00535	CbGeAlD
Dasatinib—EPHB3—brain—Gilles de la Tourette syndrome	0.00489	0.00533	CbGeAlD
Dasatinib—STK36—brain—Gilles de la Tourette syndrome	0.00489	0.00533	CbGeAlD
Dasatinib—MAPK14—central nervous system—Gilles de la Tourette syndrome	0.00475	0.00517	CbGeAlD
Dasatinib—FMO3—nervous system—Gilles de la Tourette syndrome	0.00474	0.00516	CbGeAlD
Dasatinib—LIMK2—brain—Gilles de la Tourette syndrome	0.00473	0.00515	CbGeAlD
Dasatinib—FGR—central nervous system—Gilles de la Tourette syndrome	0.00473	0.00515	CbGeAlD
Dasatinib—JAK2—nervous system—Gilles de la Tourette syndrome	0.00464	0.00505	CbGeAlD
Dasatinib—STK35—brain—Gilles de la Tourette syndrome	0.00458	0.00499	CbGeAlD
Dasatinib—EPHA2—nervous system—Gilles de la Tourette syndrome	0.00458	0.00499	CbGeAlD
Dasatinib—FYN—nervous system—Gilles de la Tourette syndrome	0.00458	0.00498	CbGeAlD
Dasatinib—FMO3—central nervous system—Gilles de la Tourette syndrome	0.00456	0.00497	CbGeAlD
Dasatinib—CSK—brain—Gilles de la Tourette syndrome	0.00455	0.00496	CbGeAlD
Dasatinib—HCK—brain—Gilles de la Tourette syndrome	0.0045	0.0049	CbGeAlD
Dasatinib—MAP4K5—nervous system—Gilles de la Tourette syndrome	0.00447	0.00487	CbGeAlD
Dasatinib—MAP3K3—nervous system—Gilles de la Tourette syndrome	0.00447	0.00487	CbGeAlD
Dasatinib—ABL2—brain—Gilles de la Tourette syndrome	0.00447	0.00487	CbGeAlD
Dasatinib—JAK2—central nervous system—Gilles de la Tourette syndrome	0.00447	0.00486	CbGeAlD
Dasatinib—MAP2K5—midbrain—Gilles de la Tourette syndrome	0.00445	0.00484	CbGeAlD
Dasatinib—EPHA2—central nervous system—Gilles de la Tourette syndrome	0.00441	0.00481	CbGeAlD
Dasatinib—FYN—central nervous system—Gilles de la Tourette syndrome	0.00441	0.0048	CbGeAlD
Dasatinib—CSF1R—midbrain—Gilles de la Tourette syndrome	0.00434	0.00473	CbGeAlD
Dasatinib—MAP3K3—central nervous system—Gilles de la Tourette syndrome	0.00431	0.00469	CbGeAlD
Dasatinib—MAP4K5—central nervous system—Gilles de la Tourette syndrome	0.00431	0.00469	CbGeAlD
Dasatinib—EPHB6—nervous system—Gilles de la Tourette syndrome	0.00427	0.00465	CbGeAlD
Dasatinib—RIPK2—brain—Gilles de la Tourette syndrome	0.00423	0.0046	CbGeAlD
Dasatinib—YES1—nervous system—Gilles de la Tourette syndrome	0.00413	0.0045	CbGeAlD
Dasatinib—SIK1—brain—Gilles de la Tourette syndrome	0.00413	0.0045	CbGeAlD
Dasatinib—EPHB6—central nervous system—Gilles de la Tourette syndrome	0.00411	0.00448	CbGeAlD
Dasatinib—EPHA4—brain—Gilles de la Tourette syndrome	0.00409	0.00445	CbGeAlD
Dasatinib—PDGFRA—nervous system—Gilles de la Tourette syndrome	0.00405	0.00441	CbGeAlD
Dasatinib—ERBB3—brain—Gilles de la Tourette syndrome	0.00405	0.00441	CbGeAlD
Dasatinib—MAP3K2—brain—Gilles de la Tourette syndrome	0.00401	0.00436	CbGeAlD
Dasatinib—YES1—central nervous system—Gilles de la Tourette syndrome	0.00398	0.00433	CbGeAlD
Dasatinib—SRC—nervous system—Gilles de la Tourette syndrome	0.00397	0.00433	CbGeAlD
Dasatinib—KIT—midbrain—Gilles de la Tourette syndrome	0.00394	0.00429	CbGeAlD
Dasatinib—PDGFRA—central nervous system—Gilles de la Tourette syndrome	0.0039	0.00425	CbGeAlD
Dasatinib—PDGFRB—midbrain—Gilles de la Tourette syndrome	0.00385	0.00419	CbGeAlD
Dasatinib—SRC—central nervous system—Gilles de la Tourette syndrome	0.00383	0.00417	CbGeAlD
Dasatinib—MAPK14—brain—Gilles de la Tourette syndrome	0.00377	0.0041	CbGeAlD
Dasatinib—FGR—brain—Gilles de la Tourette syndrome	0.00375	0.00409	CbGeAlD
Dasatinib—MAP2K5—nervous system—Gilles de la Tourette syndrome	0.00365	0.00398	CbGeAlD
Dasatinib—FMO3—brain—Gilles de la Tourette syndrome	0.00362	0.00395	CbGeAlD
Dasatinib—EPHB4—brain—Gilles de la Tourette syndrome	0.00357	0.00389	CbGeAlD
Dasatinib—CSF1R—nervous system—Gilles de la Tourette syndrome	0.00357	0.00388	CbGeAlD
Dasatinib—JAK2—brain—Gilles de la Tourette syndrome	0.00355	0.00386	CbGeAlD
Dasatinib—MAP2K5—central nervous system—Gilles de la Tourette syndrome	0.00352	0.00383	CbGeAlD
Dasatinib—EPHA2—brain—Gilles de la Tourette syndrome	0.0035	0.00382	CbGeAlD
Dasatinib—FYN—brain—Gilles de la Tourette syndrome	0.0035	0.00381	CbGeAlD
Dasatinib—CSF1R—central nervous system—Gilles de la Tourette syndrome	0.00343	0.00374	CbGeAlD
Dasatinib—ABL1—midbrain—Gilles de la Tourette syndrome	0.00343	0.00374	CbGeAlD
Dasatinib—MAP3K3—brain—Gilles de la Tourette syndrome	0.00342	0.00372	CbGeAlD
Dasatinib—MAP4K5—brain—Gilles de la Tourette syndrome	0.00342	0.00372	CbGeAlD
Dasatinib—EPHB6—brain—Gilles de la Tourette syndrome	0.00327	0.00356	CbGeAlD
Dasatinib—KIT—nervous system—Gilles de la Tourette syndrome	0.00324	0.00353	CbGeAlD
Dasatinib—PDGFRB—nervous system—Gilles de la Tourette syndrome	0.00316	0.00345	CbGeAlD
Dasatinib—YES1—brain—Gilles de la Tourette syndrome	0.00316	0.00344	CbGeAlD
Dasatinib—KIT—central nervous system—Gilles de la Tourette syndrome	0.00312	0.0034	CbGeAlD
Dasatinib—PDGFRA—brain—Gilles de la Tourette syndrome	0.0031	0.00337	CbGeAlD
Dasatinib—PDGFRB—central nervous system—Gilles de la Tourette syndrome	0.00305	0.00332	CbGeAlD
Dasatinib—SRC—brain—Gilles de la Tourette syndrome	0.00304	0.00331	CbGeAlD
Dasatinib—LIMK2—Sema4D in semaphorin signaling—MET—Gilles de la Tourette syndrome	0.00284	0.0347	CbGpPWpGaD
Dasatinib—HCK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00283	0.0347	CbGpPWpGaD
Dasatinib—ABL1—nervous system—Gilles de la Tourette syndrome	0.00282	0.00307	CbGeAlD
Dasatinib—MAP2K5—brain—Gilles de la Tourette syndrome	0.00279	0.00304	CbGeAlD
Dasatinib—CSF1R—brain—Gilles de la Tourette syndrome	0.00273	0.00297	CbGeAlD
Dasatinib—ABL1—central nervous system—Gilles de la Tourette syndrome	0.00271	0.00296	CbGeAlD
Dasatinib—BLK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00257	0.0314	CbGpPWpGaD
Dasatinib—FGR—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00256	0.0313	CbGpPWpGaD
Dasatinib—KIT—brain—Gilles de la Tourette syndrome	0.00248	0.0027	CbGeAlD
Dasatinib—PDGFRB—brain—Gilles de la Tourette syndrome	0.00242	0.00263	CbGeAlD
Dasatinib—CYP1B1—nervous system—Gilles de la Tourette syndrome	0.00239	0.0026	CbGeAlD
Dasatinib—CYP1B1—central nervous system—Gilles de la Tourette syndrome	0.0023	0.0025	CbGeAlD
Dasatinib—ABCG2—midbrain—Gilles de la Tourette syndrome	0.00216	0.00236	CbGeAlD
Dasatinib—ABL1—brain—Gilles de la Tourette syndrome	0.00216	0.00235	CbGeAlD
Dasatinib—YES1—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00207	0.0253	CbGpPWpGaD
Dasatinib—EPHA2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.00188	0.023	CbGpPWpGaD
Dasatinib—CSF1R—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00185	0.0226	CbGpPWpGaD
Dasatinib—CYP1B1—brain—Gilles de la Tourette syndrome	0.00183	0.00199	CbGeAlD
Dasatinib—STAT5B—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00179	0.0219	CbGpPWpGaD
Dasatinib—SIK1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00176	0.0215	CbGpPWpGaD
Dasatinib—SIK1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00171	0.0209	CbGpPWpGaD
Dasatinib—CYP1A1—nervous system—Gilles de la Tourette syndrome	0.00169	0.00184	CbGeAlD
Dasatinib—EPHA2—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	0.00163	0.0199	CbGpPWpGaD
Dasatinib—CYP1A1—central nervous system—Gilles de la Tourette syndrome	0.00163	0.00177	CbGeAlD
Dasatinib—SIK1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00159	0.0194	CbGpPWpGaD
Dasatinib—LYN—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00154	0.0188	CbGpPWpGaD
Dasatinib—FYN—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00152	0.0186	CbGpPWpGaD
Dasatinib—PTK6—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.00144	0.0176	CbGpPWpGaD
Dasatinib—MAPK14—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00142	0.0174	CbGpPWpGaD
Dasatinib—STAT5B—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.00141	0.0172	CbGpPWpGaD
Dasatinib—SIK1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.00139	0.017	CbGpPWpGaD
Dasatinib—LIMK2—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.00137	0.0168	CbGpPWpGaD
Dasatinib—ABCG2—brain—Gilles de la Tourette syndrome	0.00136	0.00148	CbGeAlD
Dasatinib—CYP1A1—brain—Gilles de la Tourette syndrome	0.00129	0.00141	CbGeAlD
Dasatinib—LCK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00126	0.0154	CbGpPWpGaD
Dasatinib—EPHA3—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.00126	0.0154	CbGpPWpGaD
Dasatinib—MAPK14—Parkinsons Disease Pathway—SLC6A3—Gilles de la Tourette syndrome	0.00124	0.0152	CbGpPWpGaD
Dasatinib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00124	0.00135	CbGeAlD
Dasatinib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00119	0.0013	CbGeAlD
Dasatinib—SRC—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00112	0.0137	CbGpPWpGaD
Dasatinib—ERBB3—a6b1 and a6b4 Integrin signaling—MET—Gilles de la Tourette syndrome	0.00107	0.0131	CbGpPWpGaD
Dasatinib—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00107	0.00116	CbGeAlD
Dasatinib—SRMS—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000995	0.0122	CbGpPWpGaD
Dasatinib—EPHA2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000978	0.012	CbGpPWpGaD
Dasatinib—ABCB1—nervous system—Gilles de la Tourette syndrome	0.000877	0.000955	CbGeAlD
Dasatinib—TXK—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000846	0.0103	CbGpPWpGaD
Dasatinib—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.000844	0.000919	CbGeAlD
Dasatinib—TNK2—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000824	0.0101	CbGpPWpGaD
Dasatinib—LIMK2—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000798	0.00976	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000787	0.00963	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000688	0.00841	CbGpPWpGaD
Dasatinib—EPHB1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000677	0.00828	CbGpPWpGaD
Dasatinib—ABCB1—brain—Gilles de la Tourette syndrome	0.00067	0.00073	CbGeAlD
Dasatinib—ERBB3—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000663	0.00811	CbGpPWpGaD
Dasatinib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000663	0.00811	CbGpPWpGaD
Dasatinib—FYN—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000656	0.00802	CbGpPWpGaD
Dasatinib—SRC—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.000637	0.00779	CbGpPWpGaD
Dasatinib—SRC—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.000622	0.00761	CbGpPWpGaD
Dasatinib—EPHA2—Direct p53 effectors—MET—Gilles de la Tourette syndrome	0.00062	0.00759	CbGpPWpGaD
Dasatinib—MAPK14—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.000575	0.00703	CbGpPWpGaD
Dasatinib—FMO3—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000566	0.00692	CbGpPWpGaD
Dasatinib—SRC—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000559	0.00684	CbGpPWpGaD
Dasatinib—ABL1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.000514	0.00629	CbGpPWpGaD
Dasatinib—FYN—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.000502	0.00614	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000492	0.00602	CbGpPWpGaD
Dasatinib—MAPK14—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.00049	0.00599	CbGpPWpGaD
Dasatinib—SRC—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000483	0.00591	CbGpPWpGaD
Dasatinib—EPHB1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000483	0.00591	CbGpPWpGaD
Dasatinib—EPHB3—Axon guidance—MET—Gilles de la Tourette syndrome	0.000457	0.00559	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000443	0.00542	CbGpPWpGaD
Dasatinib—SRC—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.00044	0.00538	CbGpPWpGaD
Dasatinib—HCK—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000408	0.00499	CbGpPWpGaD
Dasatinib—ABL2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000408	0.00499	CbGpPWpGaD
Dasatinib—EPHA3—Axon guidance—MET—Gilles de la Tourette syndrome	0.000408	0.00499	CbGpPWpGaD
Dasatinib—EPHA5—Axon guidance—MET—Gilles de la Tourette syndrome	0.000408	0.00499	CbGpPWpGaD
Dasatinib—EPHA8—Axon guidance—MET—Gilles de la Tourette syndrome	0.000393	0.00481	CbGpPWpGaD
Dasatinib—EPHB4—Axon guidance—MET—Gilles de la Tourette syndrome	0.000389	0.00476	CbGpPWpGaD
Dasatinib—LIMK2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000389	0.00476	CbGpPWpGaD
Dasatinib—EPHA4—Axon guidance—MET—Gilles de la Tourette syndrome	0.000389	0.00476	CbGpPWpGaD
Dasatinib—EPHB2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000377	0.00461	CbGpPWpGaD
Dasatinib—FMO3—Metabolism—HDC—Gilles de la Tourette syndrome	0.000374	0.00457	CbGpPWpGaD
Dasatinib—BLK—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000369	0.00452	CbGpPWpGaD
Dasatinib—FGR—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000368	0.0045	CbGpPWpGaD
Dasatinib—EPHB6—Axon guidance—MET—Gilles de la Tourette syndrome	0.000366	0.00447	CbGpPWpGaD
Dasatinib—MAP2K5—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000351	0.0043	CbGpPWpGaD
Dasatinib—EPHB3—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000326	0.00399	CbGpPWpGaD
Dasatinib—SRC—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000321	0.00393	CbGpPWpGaD
Dasatinib—EPHA2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000317	0.00388	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000315	0.00385	CbGpPWpGaD
Dasatinib—EPHA5—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000291	0.00356	CbGpPWpGaD
Dasatinib—EPHA3—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000291	0.00356	CbGpPWpGaD
Dasatinib—ABL2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000291	0.00356	CbGpPWpGaD
Dasatinib—MAPK14—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000281	0.00344	CbGpPWpGaD
Dasatinib—EPHA8—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000281	0.00343	CbGpPWpGaD
Dasatinib—LIMK2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000278	0.00339	CbGpPWpGaD
Dasatinib—EPHA4—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000278	0.00339	CbGpPWpGaD
Dasatinib—EPHB4—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000278	0.00339	CbGpPWpGaD
Dasatinib—EPHB2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000269	0.00329	CbGpPWpGaD
Dasatinib—EPHB6—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000261	0.00319	CbGpPWpGaD
Dasatinib—PDGFRA—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000251	0.00307	CbGpPWpGaD
Dasatinib—PDGFRB—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000226	0.00277	CbGpPWpGaD
Dasatinib—EPHA2—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000226	0.00277	CbGpPWpGaD
Dasatinib—FYN—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000218	0.00267	CbGpPWpGaD
Dasatinib—SRC—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000215	0.00263	CbGpPWpGaD
Dasatinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000211	0.00258	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000207	0.00253	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000201	0.00246	CbGpPWpGaD
Dasatinib—YES1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000194	0.00237	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000187	0.00229	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000168	0.00205	CbGpPWpGaD
Dasatinib—SRC—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000161	0.00197	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000153	0.00187	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000146	0.00178	CbGpPWpGaD
Dasatinib—LYN—Axon guidance—MET—Gilles de la Tourette syndrome	0.000145	0.00177	CbGpPWpGaD
Dasatinib—ABL1—Axon guidance—MET—Gilles de la Tourette syndrome	0.000144	0.00176	CbGpPWpGaD
Dasatinib—FYN—Axon guidance—MET—Gilles de la Tourette syndrome	0.000142	0.00174	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000141	0.00173	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000141	0.00173	CbGpPWpGaD
Dasatinib—YES1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000138	0.00169	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000137	0.00168	CbGpPWpGaD
Dasatinib—JAK2—Axon guidance—MET—Gilles de la Tourette syndrome	0.000135	0.00166	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000132	0.00161	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000131	0.0016	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000128	0.00156	CbGpPWpGaD
Dasatinib—ABCG2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000113	0.00139	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	0.000109	0.00134	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000106	0.0013	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000105	0.00129	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—MET—Gilles de la Tourette syndrome	0.000105	0.00128	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000103	0.00126	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000103	0.00126	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000103	0.00126	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000103	0.00126	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000102	0.00125	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000102	0.00124	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—MET—Gilles de la Tourette syndrome	9.78e-05	0.0012	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—MET—Gilles de la Tourette syndrome	9.66e-05	0.00118	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.64e-05	0.00118	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	9.63e-05	0.00118	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	9.59e-05	0.00117	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	9.53e-05	0.00117	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.35e-05	0.00114	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	9.35e-05	0.00114	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.29e-05	0.00114	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.23e-05	0.00113	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.02e-05	0.0011	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	8.94e-05	0.00109	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.71e-05	0.00107	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	8.71e-05	0.00107	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.4e-05	0.00103	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	8.25e-05	0.00101	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.15e-05	0.000997	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.91e-05	0.000968	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—MET—Gilles de la Tourette syndrome	7.49e-05	0.000916	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	7.37e-05	0.000902	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.28e-05	0.00089	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.07e-05	0.000864	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.89e-05	0.000843	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	6.72e-05	0.000821	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.69e-05	0.000818	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.67e-05	0.000816	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	6.59e-05	0.000806	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.58e-05	0.000805	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.23e-05	0.000762	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.21e-05	0.000759	CbGpPWpGaD
Dasatinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	6.13e-05	0.00075	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.1e-05	0.000746	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	6.1e-05	0.000746	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.08e-05	0.000743	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.03e-05	0.000737	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.98e-05	0.000732	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.9e-05	0.000722	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.88e-05	0.000719	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.81e-05	0.000711	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.76e-05	0.000705	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.69e-05	0.000696	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.62e-05	0.000687	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.59e-05	0.000684	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.52e-05	0.000675	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.5e-05	0.000672	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.41e-05	0.000662	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.21e-05	0.000637	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.16e-05	0.000632	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.14e-05	0.000629	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	5.09e-05	0.000622	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.98e-05	0.000609	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.84e-05	0.000592	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.61e-05	0.000564	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.51e-05	0.000551	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.41e-05	0.000539	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.37e-05	0.000534	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.28e-05	0.000524	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.99e-05	0.000488	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.93e-05	0.000481	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.85e-05	0.000471	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.79e-05	0.000464	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.65e-05	0.000446	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.6e-05	0.000441	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.16e-05	0.000386	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.79e-05	0.000342	CbGpPWpGaD
